Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
10.9 USD +3.02% Intraday chart for Sage Therapeutics, Inc. -1.89% -49.70%
May. 29 Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target MT
May. 15 Transcript : Sage Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M
MT
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Top Midday Decliners
MT
Sector Update: Health Care Stocks Advance Premarket Wednesday
MT
Sector Update: Health Care
MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday
MT
Top Premarket Decliners
MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint
MT
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
CI
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines
MT
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M
MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC
CI
Biogen, Sage Therapeutics Say Oral Pill Zurzuvae for Postpartum Depression Now Available by Prescription in US
MT
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE 50 mg (Two 25 mg Capsules Per Day) CIV
CI
Sage Therapeutics Q3 Loss Widens; Revenue Rises
MT
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
RE
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q3 Revenue $2.7M, vs. Street Est of $3.2M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.
  5. Highlights